The increasing use of the standard triple therapy for eradication of Helicobacter pylori (H. pylori) has led to an increase in the prevalence of strains resistant to existing drugs, thereby lowering the success rate of eradication therapies.
Background
Helicobacter pylori (H. pylori) has a high infection rate (approximately 50 per cent worldwide), 1 and approximately 50 per cent of the Korean population is known to be infected with H. pylori. 2 In recent years, the first-line therapy against H. pylori has been the standard triple therapy, which combines a proton pump inhibitor (PPI) and two types of antibiotics (AMX (amoxicillin) and CAM (clarithromycin) or AMX (amoxicillin) and MNZ (metronidazole)). 3 Although the eradication rate of the triple therapy varies depending on whether the patient is infected with sensitive (81-95 per cent) or resistant strains (0-48 per cent), 4 the prevalence of H. pylori resistance to these drugs has risen recently due to the growing use of these antibiotics, frequently leading to treatment failure. Further, the decreasing success rate of the triple therapy due to increasing clarithromycin resistance has become a problem worldwide. 5 Clarithromycin resistance in H. pylori is caused by a point mutation in the V domain of the 23S rRNA gene, most commonly A2143G, A2142G, and A2142C. 6 Previous studies have reported that 23S rRNA mutations at base pairs 2057-2611 impact erythromycin efficacy by reducing the affinity of erythromycin for ribosomes. DNA extraction DNA to be used for clarithromycin resistance gene testing was extracted from residual specimens after performing RUT. Nucleic acid extraction was performed using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol, with the QIAcube system (Qiagen), which is an automated system for DNA extraction.
DPO-based multiplex PCR
DPO-based multiplex PCR was performed using residual samples collected during gastric endoscopy on patients undergoing a routine health examination.
The primers and probes were designed using the portion of the H. pylori genome that codes for the 5ʹ-untranslated region. Specimens collected for DNA extraction underwent extraction on the same day or were stored at 4°C for nucleic acid extraction on the following day. For PCR specimens, nucleic acid extraction was performed using a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's protocol, with the QIAcube system (Qiagen). H. pylori PCR was performed using 40μL of filtrate that had been passed through a QIAamp Spin column (Qiagen). The extracted DNA was stored at −80°C until use for DPO-based multiplex PCR. The stored specimens were assayed for H. pylori using a Seeplex® H. pylori-ClaR ACE Detection kit (Seegene, Seoul, Korea) based on a 5ʹ non-coding region (NCR) of a highly conserved portion in the H. pylori genome, according to the manufacturer's protocol. 
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Results
We performed DPO-based multiplex PCR on 469 randomly selected specimens (413 positive, 56 negative). A total of 89.1 per cent of the samples were positive according to DPO-based multiplex PCR and 95.9 per cent (450 of 469) agreement with the RUT results ( Table 1 ). The remaining 19 cases that showed disparity between the two tests were analyzed. Seven specimens (1.5 per cent) were positive according to RUT but negative according to DPO-based multiplex PCR, whereas 12 specimens (2.6 per cent) were negative according to RUT but positive according to DPObased multiplex PCR.
The A2142G mutation was detected in 16 specimens (3.4 per cent) and the A2143G mutation was detected in 94 specimens (20.0 per cent). Multi-mutation was detected in two specimens (0.4 per cent) ( Table 1) . H. pylori-specific sequencing was performed on the two specimens with both mutations. Both A and G peaks were detected at the mutation target site that causes drug resistance (Figure 1 ). In this study, we investigated the effectiveness of DPObased multiplex PCR using residual specimens from RUT for detecting clarithromycin resistance and determined the prevalence of clarithromycin resistance in the Cheonan area.
A total of 89.1 per cent of the 469 H. pylori specimens analyzed with DPO-based multiplex PCR were positive, which was in 95.4 per cent agreement with the RUT results (88.1 per cent positive on RUT). This result is similar to that of a previous study that employed DPO-based multiplex PCR using residual specimens from a RUT kit; 74.3 per cent of the specimens were positive for H. pylori by RUT whereas 97.1 per cent of the specimens were positive for the DPObased multiplex PCR, suggesting that the latter test has a higher sensitivity. 13 We checked for A2142G and A2143G mutations related to clarithromycin resistance through DPO-based multiplex PCR. The results showed that 23.0 per cent (108/469) contained a mutation for clarithromycin resistance, similar to a previous finding that in Korea the rate of primary clarithromycin resistance is approximately 20 per cent (17.2-23.7 per cent, p=0.323).
14 Notably, we observed a high clarithromycin resistance even though our study population was the general public undergoing routine health examination, not patients. Although reports that the acquisition of H. pylori resistance has risen due to the use of clarithromycin to treat respiratory infections 15 and that previous eradication therapy is related to clarithromycin resistance 14 suggest that these factors have increased resistance, it is difficult to definitively confirm the direct causes of the rising prevalence of resistance because the use of specimens from individuals undergoing health examinations who are apparently asymptomatic prevents us from confirming their previous and current drug regimens.
The A2142G mutation was detected in 16 specimens (3.4 per cent), whereas the A2143G mutation was detected in 94 specimens (20.0 per cent), indicating that the latter mutation is more common. Our results are in line with previous reports that the A2143G mutation has a greater impact on primary clarithromycin resistance than the A2142G mutation, 16 and that the A2143G point mutation is dominant over the A2142G point mutation. 17 In terms of regional distribution, clarithromycin resistance is highly prevalent in East Asian regions, such as Japan, 18 and least prevalent in Southeast Asian regions, 19 suggesting the possibility that cultural, regional, and climatic differences play a role in the varying mutation rates.
Interestingly, both the A2143G and A2142G mutations were detected in two specimens (0.4 per cent). Previous reports have speculated that such specimens may be infected by hetero-resistant strains, where both the wild-type and mutated strain coexist, or that they may be infected by both susceptible and resistant bacterial strains. H. pylori infections are more common in Korea than in more developed countries, with a high risk for multiple infections. 20 A prior study that performed genotyping for clarithromycin resistance via DPO-based multiplex PCR identified cases in which the A2142G and A2143G mutations were both present. Such cases, however, also showed disagreement between genotype and phenotype, with a sensitivity for phenotypes, and the authors questioned whether the 23S rRNA mutation leads to absolute resistance, 20 calling for additional studies to shed light on this matter.
This study has a few limitations. First, although the subjects were individuals undergoing routine health examinations, it is not certain that all subjects were healthy, due to the lack of data on underlying diseases or antibiotic exposure.
Hence, these data on clarithromycin resistance should be interpreted carefully. Second, despite the fact that the specimens for RUT and DPO-based multiplex PCR were obtained from the same area of the same subject, the time interval between the two tests leaves the possibility that specimen management and experimental mismatch.
Conclusion
This study is the first to investigate the prevalence of clarithromycin resistance and types of mutations in the Cheonan area using DPO-based multiplex PCR. Information on national and regional antibiotic resistance rates is required to establish effective H. pylori eradication therapies, and findings in these studies will form the basis for future investigation. Currently in Korea, not all university hospitals report antibiotic resistance rates for H. pylori. However, resistance rates vary heavily across antibiotics, and no clear evidence has been presented that elucidates the cause of the variation. Therefore, it is important to establish a standardized reference system to integrate studies conducted by multiple institutions and a central system to effectively manage the H. pylori antibiotics resistant data, to form the basis for additional studies. 
